Incyte Stock Forecast, Price & News

Incyte's stock was trading at $71.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INCY shares have increased by 36.1% and is now trading at $97.89.
View which stocks have been most impacted by COVID-19.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last twelve months. There are currently 9 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Incyte stock.
View analyst ratings for Incyte or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Incyte a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Incyte wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

1,448 employees have rated Incyte CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Incyte's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Incyte is scheduled to release its next quarterly earnings announcement on Tuesday, February 9th 2021.
View our earnings forecast for Incyte.

Incyte will be holding an earnings conference call on Tuesday, February 9th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Incyte Co. (NASDAQ:INCY) posted its earnings results on Thursday, November, 5th. The biopharmaceutical company reported $0.23 earnings per share for the quarter, missing the consensus estimate of $0.46 by $0.23. The biopharmaceutical company had revenue of $620.64 million for the quarter, compared to analysts' expectations of $622.48 million. Incyte had a negative net margin of 13.62% and a negative return on equity of 13.66%. The firm's quarterly revenue was up 12.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.82 earnings per share.
View Incyte's earnings history.

21 analysts have issued 12 month target prices for Incyte's shares. Their forecasts range from $86.00 to $124.00. On average, they expect Incyte's share price to reach $103.56 in the next twelve months. This suggests a possible upside of 5.8% from the stock's current price.
View analysts' price targets for Incyte or view Wall Street analyst' top-rated stocks.

Some companies that are related to Incyte include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Novavax (NVAX) and United Therapeutics (UTHR).
View all of INCY's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Incyte's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.26%), Frontier Capital Management Co. LLC (0.25%), Manning & Napier Group LLC (0.22%), Exchange Traded Concepts LLC (0.01%), State of Alaska Department of Revenue (0.01%) and DNB Asset Management AS (0.01%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jean Jacques Bienaime, Jonathan Elliott Dickinson, Maria E Pasquale, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends for Incyte.

INCY stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Pacer Advisors Inc., Crossmark Global Holdings Inc., Tributary Capital Management LLC, Manning & Napier Group LLC, State of Alaska Department of Revenue, and NuWave Investment Management LLC. Company insiders that have sold Incyte company stock in the last year include Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Paul Trower, Paula J Swain, Steven H Stein, and Yao Wenqing.
View insider buying and selling activity for Incyte or view top insider-selling stocks.

INCY stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Exchange Traded Concepts LLC, Louisiana State Employees Retirement System, Altfest L J & Co. Inc., IFM Investors Pty Ltd, DNB Asset Management AS, and Newfound Research LLC.
View insider buying and selling activity for Incyte or or view top insider-buying stocks.

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INCY stock can currently be purchased for approximately $97.89.

Incyte has a market capitalization of $21.44 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis. Incyte employs 1,456 workers across the globe.

The official website for Incyte is www.incyte.com.

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]